Literature DB >> 9719093

Evaluating isovelocity surface area flow convergence method with finite element modeling.

C G DeGroff1, A M Baptista, D J Sahn.   

Abstract

Through numerical experimentation we investigated the isovelocity surface area flow convergence method used in estimating regurgitant valve flow rates. Recent advances in three-dimensional color Doppler flow imaging have created renewed interest in this method. Experimentation was based on the use of depth-averaged finite element models of the left heart. The heart models studied varied from "synthetic" representations to a model of a left heart traced from an actual echocardiographic image of a patient with a prolapsed mitral valve. The isovelocity surface area flow convergence method overestimated regurgitant flow rates throughout the Nyquist limits considered with a critical Nyquist limit in which this overestimation is minimized. The angle dependence of Doppler color flow imaging partially corrects for this overestimation. The isovelocity surface area flow convergence method is a viable alternative to methods currently in use. Through numerical experimentation, we have begun to shed light on the inaccuracies inherent in this flow convergence method.

Entities:  

Mesh:

Year:  1998        PMID: 9719093     DOI: 10.1016/s0894-7317(98)70056-2

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  2 in total

1.  Flow in the early embryonic human heart: a numerical study.

Authors:  C G DeGroff; B L Thornburg; J O Pentecost; K L Thornburg; M Gharib; D J Sahn; A Baptista
Journal:  Pediatr Cardiol       Date:  2003-03-14       Impact factor: 1.655

2.  In vitro validation of real-time three-dimensional color Doppler echocardiography for direct measurement of proximal isovelocity surface area in mitral regurgitation.

Authors:  Stephen H Little; Stephen R Igo; Bahar Pirat; Marti McCulloch; Craig J Hartley; Yukihiko Nosé; William A Zoghbi
Journal:  Am J Cardiol       Date:  2007-04-09       Impact factor: 2.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.